Serum levels of thiobarbituric acid-reactive substances are associated with risk of coronary heart disease

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 7, 2011, Pages 584-591

  Tanaka, Shin Ichiro ^a   Miki, Tetsuo ^a   Sha, Shoto ^a   Hirata, Ken Ichi ^b   Ishikawa, Yuichi ^c   Yokoyama, Mitsuhiro ^d  

^a Toyooka Hospital Hidaka Medical Center   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

Author keywords

Cohort study; Coronary heart disease (CHD); Lipid peroxide; Thiobarbituric acid reactive substances (TBARS)

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS SURGERY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; JAPANESE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BODY MASS INDEX; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; JAPAN; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 79960874367     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.6585     Document Type: Article

References (38)

1. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A, 1984; 81: 3883-3887
2. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 1991; 88: 1785-1792
3. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 1997; 272: 20963-20966
4. Haberland ME, Fong D, Cheng L: Malondialdehydealtered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science, 1988; 241: 215-218
5. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A, 1989; 86: 1372-1376
6. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest, 1994; 94: 437-444
7. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD: Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation, 2001; 103: 2277-2282
8. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M: Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)Hoxidase. Arterioscler Thromb Vasc Biol, 2002; 22: 1838-1844
9. Patton S, Kurtz GW: 2-Thiobarbituric Acid as a Reagent for Detecting Milk Fat Oxidation. J Dairy Sci, 1951; 34: 669-674
10. Yagi K: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med, 1976; 15: 212-216
11. Ohkawa H, Ohishi N, Yagi K: Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res, 1978; 19: 1053-1057
12. Halliwell B, Gutteridge JMG: Free Radicals in Biology and Medicine. Fourth Edition., ed. pp326-328, Oxford University Press, New York, 2007
13. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP: Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol, 2004; 44: 1996-2002
14. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation, 2005; 112: 651-657
15. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S: Oxidized phospholipids, lipoprot ein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol, 2007; 27: 1788-1795
16. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007; 50: 159-165
17. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med, 2003; 349: 1605-1613
18. Ishikawa Y, Nobusawa A, Fujioka Y, Takahashi A, Taniguchi T, Tanaka S, Miki T, Hirouchi H, Yokoyama M: Diet and Cardiovascular Disease: The Past, the present and the Future. In: Pietinen C, Nishida C, Khaltaev N eds. Proceedings of the 2nd WHO symposium on Health Issues for the 21st Century: Nutrition and Quality of Life, 1993: 157-168
19. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and casefatality rates in 38 populations from 21countries in four continents. Circulation, 1994; 90: 583-612
20. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation, 1979; 59: 607-609
21. Ledwozyw A, Michalak J, Stepien A, Kadziolka A: The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta, 1986; 155: 275-283
22. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K: Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med, 1981; 25: 373-378
23. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedeljković S, Nissinen A, Toshima H: Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twentyfive-year follow-up of the seven countries study. Jama, 1995; 274: 131-136
24. Zhou BF, Stamler J, Dennis B, Moag-Stahlberg A, Okuda N, Robertson C, Zhao L, Chan Q, Elliott P: Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens, 2003; 17: 623-630
25. Ueshima H: Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb, 2007; 14: 278-286
26. Robertson TL, Kato H, Rhoads GG, Kagan A, Marmot M, Syme SL, Gordon T, Worth RM, Belsky JL, Dock DS, Miyanishi M, Kawamoto S: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol, 1977; 39: 239-243
27. Niehaus WG Jr, Samuelsson B: Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem, 1968; 6: 126-130
28. Shimizu T, Kondo K, Hayaishi O: Role of prostaglandin endoperoxides in the serum thiobarbituric acid reaction. Arch Biochem Biophys, 1981; 206: 271-276
29. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
30. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, the Pravastatin or Atorvastatin Evaluation and InfectionTherapy-Thrombolysis in Myocardial Infarction, Investigators: C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med, 2005; 352: 20-28
31. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
32. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui de X, Regan JW, Smith WL: Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem, 2007; 282: 22254-22266
33. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL: Antioxidant vitamin supplements and cardiovascular disease. Circulation, 2004; 110: 637-641
34. Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A: Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol, 2002; 22: 1535-1546
35. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn CR, Bluher M: Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A, 2009; 106: 8665-8670
36. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention withantioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet, 2000; 356: 1213-1218
37. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol, 2008; 28: 341-347
38. Mora S, Rifai N, Buring JE, Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation, 2008; 118: 993-1001